The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The percentage of tumour stroma (TSP) has recently been reported to be a novel independent predictor of outcome in patients with a variety of common solid organ tumours. The aim of this study was to examine the relationship between TSP, clinicopathological characteristics and outcome in patients with invasive ductal breast cancer, in particular node negative and triple negative disease. METHODS: A total of 361 patients with primary operable invasive ductal breast cancer were included in this study. The TSP was assessed visually on the haematoxylin and eosin-stained tissue sections. With a cutoff value of 50% TSP, patients with ≤ 50% stroma were classified as the low-TSP group and those with >50% stroma were classified as the high-TSP group. RESULTS: A total of 109 (30%) patients had high TSP. Patients with high TSP were old age (P=0.035), had more Her-2-positive tumours (P=0.029), low-grade tumour inflammatory infiltrate (P=0.034), low CD68+macrophage infiltrate (P<0.001), low CD4+ (P=0.023) and low CD8+ T-lymphocytes infiltrate (P=0.017), tumour recurrence (P=0.015) and shorter cancer-specific survival (P<0.001). In node-negative patients (n=207), high TSP was associated with low CD68+macrophage infiltrate (P=0.001), low CD4+ (P=0.040) and low CD8+ T-lymphocytes infiltrate (P=0.016) and shorter cancer-specific survival (P=0.005). In triple negative patients (n=151), high TSP was associated with high tumour grade (P=<0.001), lymph node positivity (P=0.027), low CD68+macrophage infiltrate (P=0.011) and shorter cancer-specific survival (P=0.035). The 15-year cancer-specific survival rate was 79% vs 21% in the low-TSP group vs high-TSP group. In multivariate survival analysis, a high TSP was associated with reduced cancer-specific survival in the whole cohort (P=0.001), node-negative patients (P=0.007) and those who received systemic adjuvant therapy (P=0.021), independent of other pathological characteristics including host inflammatory response. However, TSP was not an independent prognostic factor for triple negative patients (P=0.151). CONCLUSIONS: A high TSP in primary operable invasive ductal breast cancer was associated with recurrence and poorer long-term survival. The inverse relation with the tumour inflammatory infiltrate highlights the importance of the amount of tumour stroma on immunological response in patients with primary operable ductal breast cancer. Implementing this simple and reproducible parameter in routine pathological examination may help optimise risk stratification in patients with invasive ductal breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 1×
“This may also implicate certain cell signalling pathways such as the common cell signalling pathway associated with inflammation; the JAK-State pathway (Yu et al, 2007, 2009).”
BackgroundMesker, W. E., Junggeburt, J. M. C., Szuhai, K., de Heer, P., Morreau, H., Tanke, H. J., & Tollenaar, R. A. E. M. (2007) · Analytical Cellular Pathology · doi:10.1155/2007/175276 · Cited by 354
Microenvironmental regulation of cancer development
Hu, M., & Polyak, K. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.12.006 · Cited by 330 · cited 2×
“Tumour stroma is thought to promote tumourigenesis by different mechanisms including remodelling of the extracellular matrix, suppression of immune response and alterations in stromal regulatory pathways affecting the motility and aggressiveness of cancer cells (Kim et al, 2005; Hu and Polyak, 2008; Cirri and Chiarugi…”
Background
Cited by
The emerging roles of circRNAs in cancer and oncology
Kristensen, L. S., Jakobsen, T., Hager, H., & Kjems, J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00585-y · Cited by 1,256
Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations
van Pelt, G. W., Kjær-Frifeldt, S., van Krieken, J. H. J. M., Al Dieri, R., Morreau, H., Tollenaar, R. A. E. M., Sørensen, F. B., & Mesker, W. E. (2018) · Virchows Archiv · doi:10.1007/s00428-018-2408-z · Cited by 192
The tumour–stroma ratio in colon cancer: the biological role and its prognostic impact
van Pelt, G. W., Sandberg, T. P., Morreau, H., Gelderblom, H., van Krieken, J. H. J. M., Tollenaar, R. A. E. M., & Mesker, W. E. (2018) · Histopathology · doi:10.1111/his.13489 · Cited by 155
Shah, S., & D’Souza, G. G. M. (2025) · Cells · doi:10.3390/cells14100732 · Cited by 83
“The ability to systematically vary the ratio of tumor to stromal cells enables the study of how microenvironmental components influence therapeutic response [207].”
3D Tumor Spheroid Models for In Vitro Therapeutic Screening of Nanoparticles
Daunys, S., Janonienė, A., Januškevičienė, I., Paškevičiūtė, M., & Petrikaitė, V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_11 · Cited by 32
Metadata
- Authors
- Gujam, F. J. A., Edwards, J., Mohammed, Z. M. A., Going, J. J., & McMillan, D. C.
- Venue
- British Journal of Cancer
- Published
- 2014-05-29
- Volume
- 111
- Issue
- 1
- Pages
- 157-165
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2046699879
- Cited by
- 113
- References
- 3
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.